X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Creditable results from Novartis - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • May 31, 2000

    Creditable results from Novartis

    Novartis has reported a 38% growth in its annual net profit on the back of a 10.3% growth in its topline.

    (Rs m) FY99 FY00 Change
    Sales 7,471 8,244 10.3%
    Other Income 235 406 72.8%
    Expenditure 6,402 6,849 7.0%
    Operating Profit (EBDIT) 1,069 1,395 30.5%
    Operating Profit Margin (%) 14.3% 16.9%  
    Interest 45 22 -51.1%
    Depreciation 142 177 24.6%
    Profit before Tax 1,117 1,602 43.4%
    Other Adjustments      
    Tax 370 568 53.5%
    Profit after Tax/(Loss) 747 1,034 38.4%
    Net profit margin (%) 10.0% 12.5%  
    Earnings per share 23 32  

    A part of the profits have accrued due to other income accruing from the grant of development rights by the company on its real estate in Goregaon (a suburb of Mumbai). These amount to almost Rs 66 m. (Novartis’ real estate can fetch it around $ 1.5 bn if it were to give development rights for its entire estate.) Even last year other income amounted to 21% of its PBT (in the current year the ratio works out to 40%) and this can be expected to recur in the current year too. If one were to exclude other income from the PBT, growth in PBT amounts to 22%. During the year the company also wrote off Rs 56 m due to VRS payments made to employees. If one were to add this back then the growth in PBT (excluding other income) works out to 27% which is quite creditable.

    Novartis India is a 50.99% subsidiary of the Novartis Switzerland, which is among the top companies in pharmaceuticals and agrochemicals. The healthcare business (this includes the vision care division and the animal health division) contributes approx. 50% of the Novartis total turnover with agro–chemicals contributing to the rest. The health care business has grown by 15% outstripping the overall pharma industry growth of 11% during the year.

    The company has 5 brands that contribute almost 45% of its formulation sales. The overall operating margins of the company are around 17% and these can be expected to increase to around 22% post the hive off of the agrochemical division.

    Besides, the company has launched five new products over the last two years all of which are out of the purview of the Drug Price Control Order. This can be expected to improve the margins further.

    The improvement in profits, the removal of a seasonal business, the introduction of new products coupled with the almost zero debt status of the company should spell good times for the company. The stock which is up almost 40% over the last week (the last time equitymaster wrote about Novartis) currently quotes at Rs 865, an earning multiple of 27 times its FY2000 earnings.

     

     

    Equitymaster requests your view! Post a comment on "Creditable results from Novartis". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    Dear PM Modi, India is Already Land of Self-Employed, and It Ain't Working(Vivek Kaul's Diary)

    Aug 21, 2017

    Most Indians who cannot find jobs, look at becoming self-employed.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Think Twice Before You Keep Money In A Savings Bank Account(Outside View)

    Aug 22, 2017

    Post demonetisation, a cut in bank savings deposits rates was in the offing.

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    NOVARTIS SHARE PRICE


    Aug 24, 2017 03:36 PM

    TRACK NOVARTIS

    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    NOVARTIS - TEVA PHARMA COMPARISON

    Compare Company With Charts

    COMPARE NOVARTIS WITH

    MARKET STATS